Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on North Carolina Wellness News.
Press releases published on May 7, 2025
Tectonic Therapeutic To Present on May 15th, 2025 at the Bank of America Securities Health Care Conference
GlobeNewswire
·
May 7, 2025
WATERTOWN, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of …
New Preclinical Data for Assembly Biosciences’ Oral Hepatitis D Virus Entry Inhibitor ABI-6250 and Next-Generation Hepatitis B Virus Capsid Assembly Modulator ABI-4334 Presented at the EASL Congress 2025
GlobeNewswire
·
May 7, 2025
– Late-breaker poster highlights preclinical profile of ABI-6250, currently in Phase 1a with data anticipated in Q3 2025 – – Second poster describes in vitro studies of effects on viral infection markers by ABI-4334, currently in Phase 1b with data …
Disc Medicine Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 7, 2025
Company remains on track to submit NDA for bitopertin in erythropoietic protoporphyria (EPP) in H2 2025 Initiated APOLLO, a confirmatory clinical trial of bitopertin in adults and adolescents with EPP Plan to initiate Phase 2 study of DISC-3405 in …
Erasca to Present at the Bank of America Securities Health Care Conference
GlobeNewswire
·
May 7, 2025
SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today …
Barinthus Bio Reports First Quarter 2025 Financial Results and Updates on Corporate Developments
GlobeNewswire
·
May 7, 2025
Highly differentiated immunotherapy for celiac disease (VTP-1000) in the clinic, with Phase 1 single ascending dose readout from AVALON expected in the third quarter of 2025; Initiation of VTP-1000 multiple ascending dose expected in the second half of …
ZyVersa Unveils Groundbreaking Potential of Inflammasome Inhibitors in Combination with GLP-1 Agonists to Address Unmet Medical Needs of People Living with Obesity; Provides R&D Update
GlobeNewswire
·
May 7, 2025
WESTON, Fla., May 07, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA), a clinical-stage biopharmaceutical company specializing in first-in-class therapies for inflammatory and renal diseases, announces significant developments for …
Arialief Complaints Explained: 2025 Customer Reviews Analyzed & Verified
GlobeNewswire
·
May 7, 2025
MIAMI, May 07, 2025 (GLOBE NEWSWIRE) -- In 2025, nerve pain remains one of the most widespread yet under-discussed health challenges. Clinically known as peripheral neuropathy, this condition affects millions worldwide and manifests in various forms, …
Cognition Therapeutics Reports Financial Results for the First Quarter 2025 and Provides Business Update
GlobeNewswire
·
May 7, 2025
- End-of-Phase 2 meeting with FDA requested for Alzheimer’s disease - - Phase 2 results in dementia with Lewy bodies accepted for oral presentation at AAIC - - Two posters at ARVO describe zervimesine's role supporting retinal cell health - PURCHASE, N.Y., …
Thérapeutique Knight annonce la relance de ONICIT® au Brésil et au Mexique
GlobeNewswire
·
May 7, 2025
MONTRÉAL, 07 mai 2025 (GLOBE NEWSWIRE) -- Thérapeutique Knight inc. (TSX : GUD) (« Knight »), société pharmaceutique spécialisée panaméricaine (hors États-Unis), a annoncé aujourd'hui la prise en charge complète des activités commerciales et la relance de …
XOMA Royalty to Present at H.C. Wainwright 1st Annual Royalty Company Virtual Conference
GlobeNewswire
·
May 7, 2025
EMERYVILLE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today its Chief Executive Officer, Owen Hughes, and Chief Investment Officer, Brad Sitko, will be featured speakers at …
InflaRx Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 7, 2025
Announces successful completion of sub-chronic and chronic toxicology studies for INF904, supporting long-term dosing in future clinical trials Multiple near-term catalysts anticipated with the potential to substantially de-risk the Company's pipeline …
BridgeBio to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2025
GlobeNewswire
·
May 7, 2025
PALO ALTO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its management team will …
Knight Therapeutics Announces Relaunch of ONICIT® in Brazil and Mexico
GlobeNewswire
·
May 7, 2025
MONTREAL, May 07, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that has assumed full commercial activities and is relaunching ONICIT® IV (palonosetron) in …
Repligen Corporation to Present at Upcoming May Investor Conferences
GlobeNewswire
·
May 7, 2025
WALTHAM, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participating at the following May investor conferences. RBC …
NewAmsterdam Pharma Announces Late-Breaking Data from BROADWAY and TANDEM Pivotal Studies Published in Leading Medical Journals and Presented at the European Atherosclerosis Society (EAS) Congress 2025
GlobeNewswire
·
May 7, 2025
– Late Breaking BROADWAY and TANDEM data presented at EAS 2025 and simultaneously published in The New England Journal of Medicine (BROADWAY) and The Lancet (TANDEM) – – Phase 3 data showed that obicetrapib as an adjunct to statins, whether in combination …
The Joint Corp. to Participate in Upcoming Investor Conferences
GlobeNewswire
·
May 7, 2025
SCOTTSDALE, Ariz., May 07, 2025 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ: JYNT), a national operator, manager, and franchisor of chiropractic clinics, announced that President and CEO Sanjiv Razdan and CFO Jake Singleton are scheduled to participate in …
Celcuity Inc. Schedules Release of First Quarter 2025 Financial Results and Webcast/Conference Call
GlobeNewswire
·
May 7, 2025
MINNEAPOLIS, May 07, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the first quarter …
Y-mAbs Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Neuroblastoma to Include Naxitamab-gqgk (DANYELZA®)
GlobeNewswire
·
May 7, 2025
PRINCETON, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody- …
Spectral Medical Announces Non-Dilutive Financing of Up to $10 Million with Vantive
GlobeNewswire
·
May 7, 2025
• Non-Dilutive Financing • Up to US$10 Million Promissory Note Provided by Vantive • If Fully Drawn, Promissory Note is Expected to Fully Fund Spectral to PMX Commercialization • Company to host Corporate Update Call on May 15, 2025 TORONTO, May 07, …
Genenta and Anemocyte announce a collaboration for the manufacturing of starting materials for cutting-edge cell-based therapies
GlobeNewswire
·
May 7, 2025
MILAN and NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, today announced a collaboration with Anemocyte, a leading Biotech Manufacturing Organization (BMO) …